TG Therapeutics Inc (NASDAQ: TGTX) is 42.68% higher on its value in year-to-date trading and has touched a low of $6.52 and a high of $26.41 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TGTX stock was last observed hovering at around $23.31 in the last trading session, with the day’s gains setting it 1.06%.
Currently trading at $24.37, the stock is 6.09% and 5.02% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.95 million and changing 4.55% at the moment leaves the stock 32.99% off its SMA200. TGTX registered 264.82% gain for a year compared to 6-month gain of 72.84%. The firm has a 50-day simple moving average (SMA 50) of $23.2057 and a 200-day simple moving average (SMA200) of $18.32505.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -1.14% loss in the last 1 month and extending the period to 3 months gives it a 20.23%, and is 6.75% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.47% over the week and 4.54% over the month.
TG Therapeutics Inc (TGTX) has around 264 employees, a market worth around $3.77B and $346.73M in sales. Current P/E ratio is 40.61 and Fwd P/E is 32.78. Profit margin for the company is 27.60%. Distance from 52-week low is 273.77% and -7.72% from its 52-week high. The company has generated returns on investments over the last 12 months (33.13%).
with sales reaching $81.23M over the same period.The EPS is expected to shrink by -41.65% this year, but quarterly earnings will post 40.50% year-over-year. Quarterly sales are estimated to grow 74.50% in year-over-year returns.
TG Therapeutics Inc (TGTX) Top Institutional Holders
337.0 institutions hold shares in TG Therapeutics Inc (TGTX), with institutional investors hold 67.76% of the company’s shares. The shares outstanding are 151.42M, and float is at 137.98M with Short Float at 24.93%. Institutions hold 61.26% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 13.69 million shares valued at $243.58 million. The investor’s holdings represent 9.3645% of the TGTX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 11.39 million shares valued at $202.6 million to account for 7.7891 of the shares outstanding. The other top investors are STATE STREET CORP which holds 6.7 million shares representing 4.5798% and valued at over $119.12 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 2.4934 of the shares totaling 3.65 million with a market value of $64.85 million.
TG Therapeutics Inc (TGTX) Insider Activity
The most recent transaction is an insider sale by Lonial Sagar, the company’s Director. SEC filings show that Lonial Sagar sold 16,348 shares of the company’s common stock on Jun 20 ’24 at a price of $16.87 per share for a total of $0.28 million. Following the sale, the insider now owns 0.11 million shares.
TG Therapeutics Inc disclosed in a document filed with the SEC on Jun 17 ’24 that Lonial Sagar (Director) sold a total of 9,585 shares of the company’s common stock. The trade occurred on Jun 17 ’24 and was made at $16.39 per share for $0.16 million. Following the transaction, the insider now directly holds 99293.0 shares of the TGTX stock.
Still, SEC filings show that on Mar 13 ’24, Lonial Sagar (Director) disposed off 5,000 shares at an average price of $15.94 for $79675.0. The insider now directly holds 108,878 shares of TG Therapeutics Inc (TGTX).
